Pediatričeskaâ Farmakologiâ | |
Universal information structure as a tool of long-term follow-up monitoring in allergology | |
L.S. Namazova-Baranova1  A.Yu. Tomilova2  Yu.G. Levina2  A.A. Alekseeva2  K.S. Volkov2  L.R. Selimzyanova2  N.I. Voznesenskaya2  E.V. Antonova2  K.E. Efendieva2  V.I. Smirnov3  E.A. Dobrynina3  E.A. Promyslova3  E.A. Vishneva3  | |
[1] Scientific Center of Children’s Health, Moscow, Russian FederationSechenov First Moscow State Medical University, Russian FederationPirogov Russian National Medical Research University, Moscow, Russian Federation;Scientific Center of Children’s Health, Moscow, Russian FederationSechenov First Moscow State Medical University, Russian Federation;Scientific Center of Children’s Health, Moscow, Russian Federation; | |
关键词: регистр; система длительного динамического мониторинга; эффективность; безопасность; бронхиальная астма тяжелого персистирующего неконтролируемого течения; омализумаб; дети; | |
DOI : 10.15690/pf.v11i5.1167 | |
来源: DOAJ |
【 摘 要 】
The article is dedicated to the issues of organization of long-term follow-up monitoring of the patient population in real clinical practice. Every medical intervention is analyzed from the position of positive evidence of its effectiveness, safety and clinical-economic benefits. Although randomized clinical trials (RCTs) are the gold standard of evidence-based medicine, they feature a range of drawbacks; in some cases, such trials are infeasible are extremely complicated to perform due to certain aspects. Along with that, results of RCTs may not completely correlate with clinical practice. Thus, a register – a system of long-term clinical monitoring of a patient population – is a significant source of information on effectiveness and safety of medical interventions. This tool of follow-up observation of a patient’s condition is irreplaceable in medicine, particularly, in allergology both for epidemiological purposes and to assess effectiveness and safety of therapeutic interventions: e.g., use of IgE antibodies – biopharmaceutical omalizumab.Keywords: register, long-term follow-up monitoring system, effectiveness, safety, uncontrolled severe persisting bronchial asthma, omalizumab, children.
【 授权许可】
Unknown